Cardio- and reno-protective effect of remote ischemic preconditioning in patients undergoing percutaneous coronary intervention. A prospective, non-randomized controlled trial

AbstractObjectivesThis study assessed the cardio- and renoprotective effect of remote ischemic Preconditioning (PreC) in patients undergoing percutaneous coronary intervention (PCI).BackgroundMyocyte necrosis and contrast induced nephropathy (CIN) occur frequently in PCI and are associated with subsequent cardiovascular events. Methods: Two hundred consecutive patients undergoing elective PCI with normal baseline troponin-I (cTnI) values were recruited. Subjects were systematically allocated into 2 groups: 100 patients received PreC (created by three 5min inflations of a blood pressure cuff to 200mmHg around the upper arm, separated by 5min intervals of reperfusion) <2h before the PCI procedure, and control group (n=100).ResultsThe incidence of PCI-related myocardial infarction (MI 4a) at 24h after PCI was lower in the PreC group compared with control group (41% vs 64%, P=0.02). Subjects who received PreC had significant trend toward lower incidence of CIN at 72h after contrast exposure (4 vs. 11, P=0.05) and less chest pain during stent implantation compared to control group. At 3 months, the major adverse event rate was lower in the PreC group (6 vs. 14 events; P=0.04).ConclusionsThe use of PreC<2h before PCI, reduces the incidence of PCI-related MI 4a, tends to decrease the incidence of CIN and improves ischemic symptoms in patients undergoing elective PCI. The observed cardio- and renoprotection appears to confer sustained benefit on reduced major adverse events at 3 month follow-up beyond what is seen with judicious pre- and post-hydration (ClinicalTrials.gov identifier: NCT02313441)

Emergence of Escherichia coli producing OXA-48 β-lactamase in the community in Switzerland

The emergence and worldwide spread of carbapenemase-producing Enterobacteriaceae is of great concern to public health services. The aim of this study was to investigate the occurrence of carbapenemase-producing Enterobacteriaceae in the community in Switzerland.Findings: One thousand and eighty-six stool samples of healthy humans (staff members of a food-processing company which were screened for the occurrence of salmonellae) were collected in September 2014. After an initial enrichment-step, carbapenemase-producing Enterobacteriaceae were isolated from the carbapenem-containing selective medium SUPERCARBA II. Grown colonies from 11 samples were screened by PCR for the presence of bla KPC, bla NDM, bla OXA-48 and bla VIM. A single OXA-48-producing Escherichia coli was detected. Phylogenetic grouping and multi-locus sequence typing (MLST) revealed that this strain belonged to D:ST38, a type which had been previously reported in the UK, France, Lebanon and Egypt.Conclusions: The results of this study show that OXA-48-producing Enterobacteriaceae have started to spread into the community in Switzerland, and a continuous monitoring is necessary to better understand their dissemination in the human population as well as in animals and the environment

Rapid polymyxin NP test for the detection of polymyxin resistance mediated by the MCR-1/MCR-2 genes

The Rapid Polymyxin NP test has been recently developed to rapidly detect polymyxin resistance in Enterobacteriaceae. Here we evaluated this test for detecting MCR- 1/MCR-2-producing Enterobacteriaceae using a collection of 70 non-redundant strains either recovered from the environment, animals, or humans. Sensitivity and specificity were found to be 100%

Full genome sequence of pT3, a multiresistant plasmid carrying the mcr-3.5 colistin resistance gene, recovered from an extended-spectrum-β-lactamase-producing Escherichia coli isolate from crickets sold as food

Here, we sequenced multidrug resistance plasmid pT3, which encodes mcr-3.5 and other resistance genes. The cooccurrence of mcr genes and other resistance genes on a single plasmid is of concern

Conversations About Responsible Nanoresearch

There is currently a strong focus on responsible research in relation to the development of nanoscience and nanotechnology. This study presents a series of conversations with nanoresearchers, with the ‘European Commission recommendation on a code of conduct for responsible nanosciences and nanotechnologies research’ (EC-CoC) as its point of departure. Six types of reactions to the document are developed, illustrating the diversity existing within the scientific community in responses towards this kind of new approaches to governance. Three broad notions of responsible nanoresearch are presented. The article concludes by arguing that while the suggestion put forward in the EC-CoC brings the concept of responsible nanoresearch a long way, one crucial element is to be wanted, namely responsible nanoresearch as increased awareness of moral choices